ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
October 31, 2019 02:00 ET
|
ObsEva SA
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
October 11, 2019 01:00 ET
|
ObsEva SA
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while...
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
October 09, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019
September 27, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva announces new composition of its Executive Committee
September 11, 2019 16:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
September 03, 2019 01:00 ET
|
ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
ObsEva SA to Participate in Upcoming Investor Conferences
August 30, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13-14, 2019
August 09, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – August 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization...
ObsEva Reports Second Quarter 2019 Financial Results
August 07, 2019 01:00 ET
|
ObsEva SA
Multiple Major Milestones Expected This Year- Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban - Nolasiban MAA submission targeted for year- end 2019- Q4:19 Phase 3 data for...
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
August 07, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and...